phage endolysin, lys46, bactericidal properties against Gram-negative bacteria.

BACKGROUND AND OBJECTIVES

The great potential of bacteriophage for removing pathogen bacteria via targeting the cell wall is highly concerned. With a priority for overcoming drug-resistance, we screened against endolysins targeting Gram-negative bacteria to introduce a new antibacterial agent. This study was aimed to identify endolysins from the lysogenic phage of the family in

MATERIALS AND METHODS

The strain DDBCC46 was isolated from a preliminary antibacterial screening program. The endolysin (s) was extracted, concentrated with ammonium sulfate saturation, and their activity evaluated against the indicator bacteria. The phage particles were extracted from the bacteria using the minimum inhibition concentration of mitomycin C, followed by testing the phage inhibitory effect on the growth of indicator bacteria. The NCBI, Virus-Host DB, and EXPASY databases were used to obtain and confirm the sequences of the genes encoding PG hydrolases in phages hosted in

RESULTS

An 816 bp gene encoding an endolysin enzyme, was approved in the DDBCC 46, with specific primers of phage SPP1. The purified-endolysin indicated antibacterial activity against , (sp), and . SDS-PAGE profiling followed by silica gel purification, led to introduce Lys46 as a therapeutic product and food preservative.

CONCLUSION

lys46 showed antibacterial effects on the common Gram-negative pathogens in clinics and food industries; and (sp).